Reglerad
- Risknivå
- Högst
- Risk–avkastning
- Dålig
- Börja från
- €100
Finansieringen är avslutad. Sidan ligger kvar som referens; liknande öppna projekt finns nedan.
Dendropharm
Tyskland
Nanotechnology for Potent Painkillers Without Addiction or Sedation
Nyckeltal
- Beräknad avkastning
- 6.8–8.16×
- plattformens uppskattning
- Värdering
- €10,000,000
- Börja från
- €100
- Målbelopp
- €1,000,000
Vad du äger, hur det kan löna sig, och när
Hur kan det löna sig?
Plattformen uppskattar 6.8–8.16×
Oftast bara om bolaget säljs eller börsnoteras. Uppskattningarna är plattformens egna påståenden.
Ditt kapital är i riskzonen. De flesta startups misslyckas; uppskattningarna är plattformens egna påståenden. Andelar är svåra att sälja före en exit.
Skulle AI investera?
AI 51 MedelVår AI ger det här projektet 51 av 100: Medel. Så fungerar AI-betyget
Information, inte personlig investeringsrådgivning. AI-betyget bedömer de dokument som plattformen publicerar, kan vara fel och förutspår inte avkastning.
AI-analys
AIDendroPharm GmbH — Crowdfunding Investor Memo
Nanotechnology for potent painkillers without addiction or sedation.
Sector: Pharma / nanotech drug delivery (deeptech, regulated) · Stage: Pre-clinical (Phase I planned Q3 2026) · HQ: Berlin, Germany · Raise: EUR 100k threshold – EUR 1.0m maximum
|
|
Why this score: |
|
AI SCORE |
|
|
51 / 100 |
|
|
⚠️ Caution |
|
|
|
|
|
|
|
|
ℹ️ This is not investment advice. The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data. |
🏢 Company description
DendroPharm GmbH (Berlin; HRB 151543 B) is a pharmaceutical R&D and contract-manufacturing company developing a nano-carrier platform branded “NanoPain™” / “NanoOpiate.” The company reports the carrier is too large to cross the blood-brain barrier, so it delivers an already-approved opioid to inflamed or post-operative tissue rather than the brain, aiming to relieve pain without the addiction and respiratory-depression risks of conventional opioids; the intravenous candidate is “DENA-19.” Founded in 2013 as a spin-off from Freie Universität Berlin (the project team reports it “took over the project in 2017”), it is led by founder/CEO Dr. Sam Dylan Moré, who holds 56.39% of the equity. The company reports a 12-person specialist team across more than 650 sqm including 300 sqm of cleanrooms and 5 analytical laboratories, ISO 9001 certification since 2015, GMP certification in 2022 (LaGeSo), and a completed manufacturing-authorisation inspection in September 2025. Current revenue is project/CDMO-based (the company reports ~EUR 600,000 of 2026 customer inquiries) alongside a veterinary cat-ointment out-licensed in 2021 and expected to be approved in 2026. This round — a profit-participating subordinated loan with an EUR 100,000 threshold and EUR 1,000,000 maximum — is earmarked to fund the first human clinical trial (Phase I) and to advance out-licensing of the Nano-Pain technology. The company separately plans a EUR 3–6m venture-capital equity round to enable Phase II in 2027.
🎯 Potential returns
|
Target return |
Time horizon |
Target basis |
AI view on reaching this goal |
|
🎯 6.80–8.16x |
⏱ ~5 yrs (to 30.04.2031) |
Company-provided — the company states 48% (base) to 52% (target) IRR per year over a 5-year period, i.e. 6.80x–8.16x. |
Plausible only on a successful out-licensing exit; under the VIB’s neutral/negative cases the multiple is not achieved and capital loss is possible. |
📈 Path to target return
|
Company methodology |
Returns are success-based, not contractual. During the term the investor earns an annual ‘success interest’ equal to their participation quota × the company’s prior-year net profit; at the end of term a ‘bonus interest’ based on company value (or, absent a recent financing round, 100% of last-year revenue); and, on a sale of >50% of shares/assets, an ‘exit interest’ (a pro-rata share of net proceeds) plus principal back. The 48–52% IRR / 6.8–8.16x figures are the company’s modelled outputs assuming positive growth and a successful out-licensing exit. |
|
Comparable exits cited |
Not disclosed in provided materials. The company estimates lifetime out-licensing revenue of EUR 1.2–1.8bn over the patent term (company-stated, unverified), with 20–30% within the first four years. |
|
Milestones expected |
|
💶 Valuation
|
Pre-money valuation |
EUR 10.0m (set by the issuer, before the campaign). |
|
Post-money valuation |
EUR 11.0m implied at the EUR 1.0m maximum raise (derived). |
|
Instrument |
Partiarisches Nachrangdarlehen — a profit-participating subordinated loan. This is NOT equity: the investor receives no shares and no ownership. |
|
How the valuation was set |
Methodology not disclosed in provided materials — the EUR 10m figure is stated as issuer-determined, with no DCF or comparables basis provided. |
|
External benchmarks |
Insufficient comparables for this sector and stage; no third-party valuation was found in public sources. The asset is pre-Phase-I, so the figure is forward-looking on out-licensing potential. |
|
Notable terms |
A ~10% valuation bonus applies to investors within 31 days of public presentation (EUR 100 → 0.001000% participation quota vs 0.000909% standard). Issuer-borne costs total 15% of amounts raised (FunderNation 6%, pooling ~6%, marketing up to 3%). |
📜 Instrument & investor terms
What you own
You own a profit-participating subordinated loan (German: partiarisches Nachrangdarlehen), not shares. There is no share class because this is debt, not equity — you become a lender to the company, not a co-owner, and you do not appear on the company’s cap table. The loan is made directly to DendroPharm (not through a nominee or SPV), but a separate pooling agreement via FunderNation Support UG provides a collective coordination procedure (for example, to negotiate a whole-loan buy-…
Hela analysen tar upp låntagaren eller bolaget, säkerheten, kassaflödet, riskerna och ett omdöme. Logga in för att läsa den.
Information, inte personlig investeringsrådgivning. AI-betyget bedömer de dokument som plattformen publicerar, kan vara fel och förutspår inte avkastning.
Fråga AI om det här projektet
Logga in för att fråga AI om projektets dokument.
Logga inGillar du projektet?
👍 Ja · 0 👎 Nej · 0
Kommentarer · 0
- Inga kommentarer än.
Plattformen och liknande projekt
Erbjuds på
Liknande öppna projekt
Kepplair Evolution
Sowefund
- Beräknad avkastning
- upp till 7×
- plattformens uppskattning
- Värdering
- €60,000,000
Mål: €9m
Från €500
Se projektet
Wind Fisher
Sowefund
- Beräknad avkastning
- upp till 10×
- plattformens uppskattning
- Värdering
- €9,961,800
Mål: €600k
Från €1,000
Se projektet
Blumana
Sowefund
- Beräknad avkastning
- upp till 28×
- plattformens uppskattning
- Värdering
- €2,799,571
Mål: €750k
Från €1,000
Se projektet